Nuvectis Pharma, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to conduct a public offering of 5,000,000 shares of common stock at $20.00 per share. The company expects to receive approximately $93 million in net proceeds, or up to $107 million if underwriters exercise their 30-day option to purchase an additional 750,000 shares. The transaction is expected to close on July 1, 2026. Nuvectis Pharma, Inc. is a pharmaceutical company focused on developing and commercializing therapeutic products.
